Gossamer Bio, Inc.
corporate_fare Company Profile
Gossamer Bio, Inc. (NASDAQ:GOSS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 45 items for GOSS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for GOSS spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- Gossamer Bio Q3 Loss Narrows to $48M; Cash Runs Only Into Q1 2027
- Gossamer Bio Submits First NDA for Seralutinib in PAH
- Gossamer Bio Submits First NDA to FDA for Seralutinib in PAH
- Gossamer Bio Sets October 27 Vote on Up to 20.1M Share Issuance for $250M Private Placement
- Gossamer Bio Completes 1-for-80 Reverse Split to Regain Nasdaq Compliance
Financial Snapshot
Short Interest & Short Volume
7.52 days to coverFINRA reported short interest of 1,339,230 shares in GOSS as of the October 30, 2026 settlement, a 6.7% decrease from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 44.8% of GOSS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for GOSS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.
Shareholder Vote on Distressed Debt Exchange Dilution · Proposed Increase in Authorized Shares
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →